Stay updated with breaking news from Valuating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary endpoint of overall survival compared to chemotherapy alone - - Data support the
Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer AMEERA-3 trial did not meet primary endpoint of improving progression-free survivalOngoing
-- Teprotumumab is marketed under the brand name TEPEZZA in the United States -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical
BAAR, Switzerland, Feb. 23, 2022 /PRNewswire/ -- Orpha Labs AG, a clinical-stage biopharmaceutical company focused on diseases with unmet needs, today announced the initiation of the Phase III
- Data Supported juMPStart Trial Evaluating One-Time, Systemic Administration of HMI-203 in ERT-Treated Adults - - Details of HMI-203 Clinical Trial Design and Encouraging Preclinical Data... | February 10, 2022